background: Male infertility caused by a maturation arrest of spermatogenesis is a condition with an abrupt stop in spermatogenesis, mostly at the level of primary spermatocytes. The etiology remains largely unknown.
Introduction
Infertility, affecting 10 -15% of couples, is a worldwide problem. Roughly half of the cases can be assigned to a male factor, mostly diagnosed by decreased sperm numbers or the complete absence of mature spermatozoa in the patients' ejaculate. Many iatrogenic and non-iatrogenic causes are known, and environmental risk factors are under scrutiny. Furthermore, combinations of acquired, environmental and congenital factors are also expected, which hampers the diagnosis. For some of the patients, a unique genetic defect is predicted. Until now, genetic causes of male infertility have especially been detected in men with a specific testicular phenotype, such as maturation arrest of spermatogenesis, or with sperm defects such as globozoospermia (Massart et al., 2012) . It remains unsure, however, for what percentage of infertile men a single genetic defect is anticipated.
Special attention should be paid to these hereditary causes, since they might potentially be transmitted to the next generation with assisted reproduction when sperm cells are available. So far, the only routine tests performed in the clinical work-up of male infertility are karyotype analysis, screening for cystic fibrosis transmembrane conductance regulator mutations (in case of suspicion of congenital bilateral absence of the vas deference) and Yq microdeletion analysis (Lissens et al., 1996; McLachlan and O'Bryan, 2010) . Some laboratories are now also routinely testing for the presence of gr/gr deletions, which are a known risk factor for male infertility (Stouffs et al., 2011a) .
During the last decade, many efforts have been made in our lab, as well as worldwide, to identify mutations in spermatogenesis genes (Tüttelmann et al., 2007; Nuti and Krausz, 2008) . The outcome has been mostly disappointing, and if a potential mutation was found, often the results could not be confirmed by other research groups.
Exceptions come from a few studies in consanguineous families and/ or from patients with specific semen abnormalities (Dam et al., 2007; Dieterich et al., 2007 ). Yet, for infertility studies, it is hard to find large families. Moreover, it is expected that mutations are present in a whole range of genes at different positions, and mutation studies are limited by the selection of genes for analysis. This selection is mostly based on previous functional studies and/or knock-out mice models (Yatsenko et al., 2010) . However, from recent expression studies, it became evident that many genes have not been studied at the functional level (Tang et al., 2007; Xiao et al., 2008) .
In mice, one approach to overcome the manual selection of genes with a known function in spermatogenesis is through 'ENU studies'. In these studies, a phenotype-driven approach is used, and therefore, a gene selection bias is avoided. The chemical mutagen N-ethyl-N-nitrosourea (ENU) is used to create random mutations in the mouse genome. After a selection on the phenotype (male infertility), the underlying mutated gene is searched (Jamsai and O'Bryan, 2010) . This approach is useful in identifying new genes potentially involved in male infertility. However, it cannot be used in human studies.
In order to study genetic defects in the human, and to overcome the selection bias, we decided to investigate whether array comparative genomic hybridization (array CGH) might be a useful tool in studying genetics of male infertility. By using array CGH, deletions and duplications/amplifications throughout the complete genome can be explored. As a consequence, there is no limit to the selection of genes. Our aims were 2-fold: first of all, we wanted to know whether deletions or duplications specifically associated with male infertility can be detected in a patient's genome, and second we wanted to investigate whether array CGH could be applied in a routine setting as part of the clinical work-up.
For this pilot study, we focused on the presence of presumed 'single defects' that are causative for male infertility, i.e. abnormalities (deletions/duplications) in individual genes (or regions) that are directly linked to the observed fertility problems. For this purpose, we investigated a small, but well-defined group of patients showing meiotic arrest in spermatogenesis. In this patient group, it is more likely that an alteration (copy number variation, CNV) in a single region or gene involved in spermatogenesis might be the underlying cause of the fertility problems.
Materials and Methods

Patients and controls
Genomic DNA was isolated from peripheral blood using Qiagen's 'QIamp Blood Maxi Kit Protocol' (Qiagen, The Netherlands) or using magnetic purification with the 'Multiprobe II Plus EX + Gripper' liquid handling robot and 'Chemagic Magnetic Separation Module I' (PerkinElmer, Belgium).
DNA samples from a total of nine azoospermic patients presenting for infertility treatment and showing maturation arrest of spermatogenesis were included in the present study. For all patients, testicular sperm extraction (TESE) was performed, during which a testicular biopsy was also taken for histological examination within the frame of their fertility work-up (Tournaye et al., 1997) . All patients showed a meiotic arrest of spermatogenesis. No spermatozoa were found, either in patients' ejaculates, or during TESE or histological examination. In all patients, the karyotype was normal, and no Yq microdeletions were detected. No gr/gr deletions were detected in these patients. Patients with a varicocoele or history of cryptorchidism were excluded from this study. A final selection criterion was based on the origin of the patients: only Caucasians originating from Belgium or the Netherlands were included.
For the control group, DNA samples from men with normozoospermia, defined by routine sperm analysis, were used. These men were also of Caucasian origin from Belgium or the Netherlands. In a first part of the study, 20 control samples were analyzed alongside with the patients through array CGH. In a second part of the study, up to 130 extra controls were investigated by qPCR: first, 70 controls were tested. When no changes were detected in this group of 70 controls, 60 more controls were analyzed in a second round of qPCRs in order to increase the statistical power (more information is provided in Supplementary data, Fig. S1 ).
Array CGH
Array CGH analysis was performed using standard methods described (Buysse et al., 2009) . In brief, 300 ng of genomic DNA was labeled with Cy3-dCTP or Cy5-dCTP (GE Healthcare, Belgium) using a Bioprime array CGH genomic labeling system (Invitrogen, Belgium). For the labeling, we used the 'triangle method': DNA samples from patients and controls were labeled and hybridized using a dye swap in trios consisting of at least one control per triangle. Samples were hybridized on 244K arrays (design ID 014693, Agilent, Belgium) for 40 h at 658C. After washing, the samples were scanned at 5 mm resolution using a DNA microarray scanner G2505B (Agilent). The scan images were analyzed using the feature extraction software 9.5.3.1 (Agilent) and further analyzed with 'arrayCGHbase' (Menten et al., 2005) . CNVs were taken into consideration when two or more flanking probes exceeded a value of the intensity ratios + four times the standard deviation of the log 2 of all intensity ratios for that experiment. Always two experiments investigating the same sample with a dye swap were compared and only when an alteration was present in both experiments, the region was included for further analysis. Inconsistencies were inspected manually.
Quantitative PCR
qPCR was performed on genomic DNA using predesigned Taqman Copy Number Assays (Applied Biosystems, Belgium) according to instructions of the manufacturer. Samples were run on the 7500 real-time PCR system (Applied Biosystems) and analyzed using CopyCaller Software provided by Applied Biosystems. The assays used are reported in Supplementary data, Table SI . In each assay, we have included the patient with the alteration detected by array CGH.
PCR analysis to detect the presence of TUSC3
For the TUSC3 gene, primers were designed in exon 1 (forward: ACCGGATGCTCTGTCAGTCT and reverse: GCCAAGGGGATC CATTCTAC) and intron 1 (forward: TGAGGAAGGATGGCTGAAT CAAGGT and reverse: AGCCAAGCTGAATTCAAGTGCCA) and were synthesized by IDT (Belgium). PCRs were performed in a 50 ml mix containing 250 ng of DNA, 1 × PCR Buffer II (Applied Biosystems), 2 mmol/l of MgCl 2 (Applied Biosystems), 0.2 mmol/l of each dNTP (GE Healthcare), 1 mmol/l of each primer and 1.25 units of Taq polymerase (Applied Biosystems). Thermocycling conditions consisted of an initial denaturation of 5 min at 948C, 30 or 35 cycles of 1 min at 948C, 1 min at 608C and 2 min at 728C and a final extension for 7 min at 728C. PCR products were analyzed on a 2% agarose gel.
Mutation analysis
The reference sequences from Genbank (NM_144713.3 for FAM82A1; NM_001113434.3 for c17orf51; NM_013386.3 for SLC25A24; NM_012240.2 for SIRT4) and genomic sequences from Ensembl (http://www.ensembl.org) were used as references to compare with our data. Primers were designed to be able to amplify and sequence the entire coding region and parts of the flanking introns (Supplementary data, Table SII) and were synthesized by IDT. PCRs and thermocycling conditions were as described above, except for the annealing temperature which was optimized for each reaction. After purification, all samples were sequenced with the primers used for amplification and run on the ABI3130xl Genetic Analyser (Applied Biosystems).
Single nucleotide changes were analyzed through Alamut (Interactive Biosoftware).
RNA expression
The presence of RNA in testicular tissues was investigated using homemade RNA. Fresh testicular tissue was obtained from patients who came to the hospital for vasectomy repair and who signed an informed consent. The histology was determined on a second biopsy and showed normal spermatogenesis. RNA was extracted using the RNeasy Mini kit (Qiagen, Belgium) after which cDNA was prepared using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Belgium). Primers for amplification of cDNA were designed according to the reference sequences and were overlapping at least one intron/exon boundary (Supplementary data, Table SIII ). All amplified fragments from testicular tissues were sequenced to confirm specific amplification.
The expression of RNA in multiple human tissues was analyzed using the Human MTC panel I and II (Clontech, Westburg, Belgium).
Proven fertile parents
In order to have access to more control data, the results of our array CGH analysis were compared with information gained from proven fertile parents. These parents were analyzed in the Center of Medical Genetics from the Ghent University Hospital in view of the investigation of a child with phenotypic abnormalities and/or mental retardation. The data were obtained using 44K or 105K arrays (Agilent) by applying the same protocol as described in this paper.
Statistical analysis
For regions analyzed by qPCR, the frequency of the rearrangements in patients and controls were compared using x 2 test. For this test, we took into consideration all patients (n ¼ 9) and controls (n ¼ 90 or n ¼ 150) analyzed by qPCR and array CGH.
Results
Nine patients with a complete meiotic arrest in spermatogenesis and 20 control patients with normal sperm parameters were analyzed using 244K oligonucleotide arrays. Overall, when considering CNVs of at least two consecutive markers, the average and median number of detected CNVs were 24.3 and 26.5 in the control group and 25.3 and 26 in the patient group. These data do not differ statistically. In the patient group, the total number of variations detected was 227 (Fig. 1) .
As a first step, we compared the data obtained from patients and controls, and excluded regions that were either deleted or amplified in both patients and controls. If a region was deleted in a patient, but amplified in a control (or vice versa), this region was kept for Array CGH analysis in male infertility further analysis. We excluded regions that do not contain any known genes (NCBI build 37), or only contain pseudogenes or non-coding RNA. After this analysis, 30 regions or genes remained in the patient group for more detailed investigation (Supplementary data, Table SIV ).
The genes AGBL4 in 1p33, FHIT in 3p14.2, QKI in 6q26, PRKG1 in 10q11.23 and CTNNA3 in 10q21.1 were not further investigated since the deletions in these genes were completely intronic. For these genes, we looked at the predicted maximum sizes of the deletions, and could conclude that the deletions were always restricted to an intron. One exception was TUSC3 in 8p22. For this gene, the minimal deleted region was limited to intron 1. However, the last fragment present 5 ′ of the gene was located 5 ′ of exon 1. Therefore, it
could not be concluded whether exon 1 was deleted or not. This patient (EMA7) was predicted to have a homozygous deletion. Primers were designed in the minimal region that was absent according to array CGH. As predicted, this primer failed to amplify in the DNA of EMA7, whereas PCR amplification was observed in a positive control. In contrast, PCR amplification was observed for a fragment located in exon 1. We could thus conclude that the deletion was limited to intron 1, and therefore, this region was not taken into further consideration. We also excluded regions with genes with a known function, not involved in spermatogenesis or genes that are not expressed in testicular tissue (Supplementary data, Table SIV) . We further eliminated a region on the X chromosome (Xq28) containing PNMA6A (paraneoplastic antigen like 6A) and MAGEA1 (melanoma antigen family A, 1). MAGEA1 is expressed in testicular tissue. Yet, multiple copies of this gene family are located in this region, and therefore, we hypothesize that one extra duplication would not influence the function of this gene (Stevenson et al., 2007; Stouffs et al., 2009 ). Furthermore, due to the presence of multiple copies of these genes, Taqman Copy Number Assays for qPCR analyses are currently not available. Similarly, region 21p11.1 contains multiple copies of genes belonging to the BAGE (B melanoma antigen) family of cancer-testis (CT) genes. These CT genes have been recently generated and amplified during evolution (Ruault et al., 2003) .
Remarkably, one large duplication of 114 markers located in chromosomal region 1q21.1 was also detected. This region contains several genes and pseudogenes. At first sight, no testis-specific gene was located in this region. A search of the literature showed that duplications of this region have been reported and might be associated with macrocephaly and developmental disorders or schizophrenia (Brunetti-Pierri et al., 2008; Mefford et al., 2008 ). Yet, the same deletions and duplications were also observed in apparently healthy parents, showing that rearrangements of this region are not associated with azoospermia. Similarly, a large duplication encompassing 8p23.1p23.2 has been described in a mother and child (Glancy et al., 2009) , partly involving the CSMD1 gene. Although the duplication size was different and the duplication was transmitted through the mother, we predicted that a duplication of CSMD1 is not important for spermatogenesis and therefore we did not select this gene for further analysis.
After this elimination, we ended up with 11 regions for further analysis (Table I) . Of the genes located in these regions, SH3D21 (C1ORF113), C17ORF51, CLEC18B, FAM82A1 and NBP4F have not been studied before. The gene TSSC1 has been described previously, but the expression in the testis remains unknown (Hu et al., 1997; Scelfo et al., 1998) . The expression of THRAP3 has already been described in multiple tissues, but testicular tissue was not included (Ito et al., 1999) . Therefore, this gene was also included in our expression study. We first analyzed, by PCR and sequence analysis, whether these genes are expressed in testicular tissues and could show that all genes, except CLEC18B were expressed in the testis. our primers were able to amplify CLEC18A, CLEC18B and CLEC18C. Yet, based on the sequence, a distinction between the three genes can be made. We were able to conclude that both CLEC18A and CLEC18C are expressed in testicular tissue, but CLEC18B is not. As a consequence, we could eliminate the region containing the CLEC18B gene from additional analyses. We further looked at the expression of the genes C1ORF113, C17ORF51, FAM82A1, NBP4F and TSSC1 in different tissues (Supplementary data, Fig. S2A -E) . All genes were expressed in most of the tissues analyzed. For C1ORF113, C17ORF51 and FAM82A1, a high expression was observed in testicular tissue (although this was not quantitatively tested).
Finally, there were 10 remaining regions that are potentially related to the fertility problems in our patients (Table I) . To further investigate the relationship between the observed deletions/duplications and male infertility, we analyzed more controls by using quantitative PCR with pre-designed copy number assays. All alterations observed by array CGH could be confirmed by qPCR. The 10 regions are described below. In this description, we always mention the minimal deletion/duplication. However, one should also take into consideration that the actual region involved might be larger. A duplication of this region was detected in EMA8. In this region, the majority (exons 2-12) of the THRAP3 gene is duplicated, as well as exons 1-10 of the C1ORF113 (¼SH3D21) gene (according to the RefSeq sequences NM_005119.3 and NM_001162530.1). A total of 130 controls were tested using a Taqman Copy Number assay located in exon 4 of the THRAP3 gene (Supplementary data,  Fig. S3) . None of the controls tested had a duplication or deletion of this region (P , 0.01).
Region 1p13.3, position 108 713 464 -108 900 204 containing SLC25A24 (5SCAMC15APC1) and NBPF4
A heterozygous deletion of this region was detected in patient EMA3. The deletion encompasses exons 1 -3 of SLC25A24 (reference sequences NM_013386 for transcript variant 1 and NM_213651 for transcript variant 2) and the complete NBPF4 gene (NM_001143989.2). A first Taqman Copy Number Assay was located at position 108735360 (NCBI build 37, exon 2). However, this fragment also appeared to be absent in 31% (22/70) of the controls tested. Since only a single patient and no controls with a deletion were detected by array CGH, we randomly picked 11 controls tested by array CGH to test again by qPCR. As expected, three of these controls (27%) had a deletion of the region where the Taqman Copy Number Assay was located. It was therefore presumed that smaller deletions are present in this region in a high percentage of the population. The database of genomic variants (projects.tcag.ca/variation/) indeed showed a small deletion that was limited to this region. Therefore, a new assay, located between the genes SLC25A24 and NBPF4 was studied. No predesigned assay was located in the NBPF4 gene. By analyzing 130 controls with this new assay, no deletion could be detected (P , 0.01). The remaining copy of the SLC25A24 gene was sequenced in patient EMA3 (having a heterozygous deletion). No changes were detected in the exons and part of the flanking introns of this gene.
Region 1p13.2, position 114 657 656 -114 814 238, containing SYT6
In EMA7, a duplication of this region was observed. This duplication involves exons 6 -8 of the SYT6 gene (NM_205848.2). A total of 130 controls who were tested by qPCR all showed a normal copy number (P , 0.01).
Region 2p25.2, position 3 062 188 -3 325 509, containing TSSC1
In EMA3, exons 4-9 of TSSC1 are duplicated. In 70 control samples tested by qPCR with an assay located in exon 6 of the TSSC1 gene, one control sample was found to have a duplication. Taking all 90 controls tested (70 by qPCR and 20 by array CGH) into consideration, no (statistical) difference was detected. Furthermore, in a diagnostic setting, we have detected a duplication in a child and his (proven) fertile father.
Region 2p22.2, position 38 085 399 -38 180 014, containing FAM82A1
The first five exons of the FAM82A1 gene (NM_144713.3) were predicted to be deleted in EMA18. We tested a total of 130 controls for the presence of copy number alterations in FAM82A1. We detected one man with a duplication of the region where the assay was located. However, no deletions were detected (P , 0.01). We also sequenced all exons and part of the flanking introns of the remaining gene copy in patient EMA18, but no mutations were detected.
Region 3q24, position 146 114 122 -146 191 793, containing PLSCR2 and LOC440981
The duplication of this region involves exons 2-9 of the PLSCR2 gene and exons 1-3 of the hypothetical protein LOC440981. The assay used to search for deletions/duplications in control samples was located in exon 5 of the PLSCR2 gene. The duplication in EMA18 could be confirmed, but no other duplications or deletions were detected in 130 controls tested (P , 0.01).
Region 5q13.2, position 70 308 101 -70 309 855, containing NAIP Through array CGH, multiple duplications have been detected encompassing this region in patients and controls. However, two deletions (minimal size: 1754 bp and maximal size: 654 kb) were only detected in two patients and in none of the controls. This deletion involves only exon 4 (minimum deletion size), containing the start codon of the gene. An assay located in exon 4 was ordered to analyze control samples. Obviously, also larger duplications, as detected using array CGH, will be visualized when using this assay. There were 70 controls tested. In this group, four controls had only a single copy of this region. As expected, we also detected multiple controls with three (n ¼ 9) copies of this region. Taking into consideration all controls tested (n ¼ 90), significantly more deletions were detected in the patient group (P ¼ 0.03).
Array CGH analysis in male infertility
Region 12q24.31, position 120 734 605-120 755 841, containing SIRT4
This deletion removes the complete SIRT4 gene in patient EMA18. The Taqman Copy Number Assay was chosen in exon 2 (containing the start codon). None of the controls tested had a deletion (P , 0.01). Therefore, we also sequenced the remaining copy of the SIRT4 gene in EMA18. No mutations could be detected.
Region 15q15.3, position 43 888 927 -43 950 720, containing CKMT1B, STRC and CATSPER2
The duplication of this region includes part of CKMT1B (exons 8-10) and the complete STRC and CATSPER2 genes. No Taqman Copy Number Assay was located in the CKMT1B gene, and there was only a single assay for STRC. The assay chosen in the CATSPER2 gene was located in exon 6. The duplication in EMA8 could be confirmed, but no other duplications were detected (P , 0.01). We did observe, however, two deletions in the control group consisting of 130 men. In a diagnostic setting, however, .25 duplications have been detected involving the CATSPER2 gene, making this a highly polymorphic region.
Region 17p11.2, position 21 370 330 -21 501 929, containing C17ORF51
This deletion encompasses the complete gene in patient EMA2. Through array CGH, one control was detected with a duplication of this region. By using qPCR with an assay located in exon 2, we detected one additional duplication out of the 130 controls tested. However, no deletions were observed (P , 0.01). The remaining allele of C17ORF51 was sequenced in patient EMA2, but no alterations were detected in this copy of the gene.
Discussion
This study is describing CNVs in association with the genetic background of male infertility. Since causes of male infertility are very heterogeneous, we decided to investigate a small yet uniform group of patients: men with a maturation arrest of spermatogenesis. For this patient group, it is more likely that a genetic defect is the cause of their fertility problem. It is known that Yq microdeletions might cause maturation arrest of spermatogenesis, especially in case of an AZFb deletion (Kleiman et al., 2011) . Furthermore, mutations in the meiosis gene SYCP3 have been described. Yet, in our patients with maturation arrest of spermatogenesis, no changes causing alterations at the protein level could be detected (Stouffs et al., 2005; Stouffs et al., 2011b) . Since mutation screening has some limitations, we decided to use array CGH to screen for deletions and duplications throughout the entire genome. Array CGH has the advantage of having no selection bias at the gene level. Therefore, our analysis is not limited to genes with a known function in spermatogenesis. However, array CGH too suffers from some limitations. First of all, the resolution is a limiting factor. We used 244K arrays with 236 381 probes spread over the genome with an average spacing of 8.9 kb (7.4 kb in RefSeq genes). Small deletions or duplications may be missed as well as point-mutations. Nowadays, high-resolution arrays with up to 2 million probes (Nimblegen) are commercially available. Furthermore, it is impossible with array CGH analysis to detect balanced inversions or translocations that might disrupt genes which are essential for meiosis or spermatogenesis. Yet, for all our patients, a karyotype analysis has been performed and hence, large rearrangements could be excluded.
In our elimination steps, we only considered protein coding genes, and all CNVs that were present in controls were also removed. As a consequence, potential 'risk factors' might be eliminated. However, the presence of such 'risk factors' influencing male infertility are more expected in oligozoospermic men than in azoospermic men with a maturation arrest of spermatogenesis. We are well aware that regulatory elements or non-coding RNAs could potentially influence spermatogenesis. It is even thought that small RNAs play an important role during spermatogenesis (He et al., 2009 ).Yet, this new area needs largely to be investigated. For this pilot study, we wanted to investigate whether CNVs of protein coding genes can be detected in infertile men.
All potentially interesting regions were further investigated through real-time PCR using Taqman Copy Number Assays. As such, all observed rearrangements were confirmed, and more controls could be analyzed. Where possible, we have chosen an assay located in an exon and in the middle of the rearrangements, to be as representative as possible for that region. When no changes are detected for the corresponding region, it can be concluded that the rearrangement observed in the patient was not present in the control group. However, when a deletion/duplication was detected in patient(s) as well as control(s), it is possible but not sure that the same alterations are present in patients and controls. Yet, the rearrangements in the genes TSSC1 and NAIP are rather small, and therefore the Taqman Copy Number Assay is more likely to be representative for the complete region. For both regions, we detected at least one alteration in our normozoospermic control group. Furthermore, alterations in the regions 2p25.2 (TSSC1) were also detected in a diagnostic setting. Deletions of the region containing the NAIP gene (5q13.2) were observed more frequently in our patient group compared with the control group. Possibly, these deletions should be considered as 'risk factors'. However, the number of patients and controls analyzed remains too small. Overall, we believe that these regions can be excluded as being causative of the fertility problems.
Eight rearrangements might be linked to the fertility problems of our patients, as they are not detected in our normozoospermic control group: four are deleted regions and four are duplications. The regions with a deletion were of particular interest since the region/ gene is disrupted or completely removed. The consequences of duplications are harder to predict. For all regions with a deletion, we have sequenced the remaining copy of the gene of interest.
A first region, located on chromosomeband 1p34.3 contains the genes THRAP3 and SH3D21 (¼C1ORF113). The latter gene has not been studied before. We could show that this gene is expressed in most of the tissues analyzed, including testis. Yet, its more specific expression pattern and function remain unknown. An SH3 domain is predicted in this protein, which is an essential domain for multiple biological processes (Mayer, 2001) . Also the THRAP3 gene is ubiquitously expressed, with highest expression in skeletal muscle and ovary (Nagase et al., 1996; Ito et al., 1999) . THRAP3 is involved in pre-mRNA splicing, an important step during spermatogenesis (Lee et al., 2010) . A total of 20 controls have been tested by array CGH and 130 controls were analyzed by qPCR. None of these 150 controls tested had a duplication or deletion of this region. As a consequence, a gain in copy number of THRAP3 and/or SH3D21 might be linked to the fertility problems observed in EMA8.
A second region was located at chromosomeband 1p13.3 and contains two genes, SLC25A24 and NBPF4. The latter gene belongs to a family of at least 22 NBPF genes that have recently been duplicated in evolution, with the majority of the copies located on chromosome 1 (Vandepoele et al., 2005) . Therefore, it is less likely that a deletion of one copy of this family will have a large impact on the fertility status of the patients. The SLC25A24 gene belongs to a family of genes that encode for mitochondrial carriers involved in the transport of adenine nucleotides (Fiermonte et al., 2004) . The SLC25A24 (¼SCAMC1¼APC1) gene is highly expressed in testicular tissue (Fiermonte et al., 2004) . Therefore, this gene is a good candidate (in)fertility gene. There are two splice variants of the SLC25A24 gene. The first Taqman Copy Number Assay that we tried was located in exon 2 which is the first exon in NM_213651 (variant 2) and includes the start codon. In transcript variant 1, this exon is missing. We noticed a high frequency of deletions involving this region in patients as well as in controls. A more detailed look at the database of genomic variants showed that this region was often involved in rearrangements. These rearrangements are limited to exon 2, and part of the flanking introns. No probes representing this region were located on the 244K arrays we used. Due to the high frequency of heterozygous deletions of this region, the importance of transcript variant 2 might be questioned. In our patient, EMA3, a heterozygous change was also detected, but involving exons 1-3. Therefore, also the start codon of transcript variant 1 is missing. The remaining gene copy was sequenced, but no changes were detected.
In a third interesting region, the SYT6 gene was partly duplicated. At first, this gene was reported not to be transcribed in spermatogenesis, but later a function in the acrosome reaction was described (Craxton and Goedert, 1999; Michaut et al., 2001) . Since it remains unsure from which stage onwards the SYT6 gene is present in spermatogenesis, we included this gene for further analyses. Yet, defects in a gene involved in the acrosome reaction will most likely not cause a maturation arrest of spermatogenesis at the meiotic level.
Similarly, we observed a duplication in a region containing the PLSCR2 gene and a hypothetical protein. The region including the complete open reading frame of PLSCR2, was duplicated in patient EMA18, but not in the 150 controls tested in total. The PLSCR2 gene shows a testis-specific expression pattern, and might be involved in sperm capacitation (Wiedmer et al., 2000; de Vries et al., 2003) . Yet, it remains unsure whether the PLSCR2 protein has a function in earlier steps of spermatogenesis and consequently whether duplications in this gene might explain the maturation arrest of spermatogenesis found in patient EMA18.
Furthermore, we detected a duplication involving the CATSPER2 gene. This gene also has a function later in spermatogenesis; it is essential for sperm motility. Yet, for the CATSPER2 protein, the expression has been detected from spermatocytes onwards (Quill et al., 2001) . Consequently, a gain in copy number of this gene might force the spermatocytes to stop developing and thereby causing maturation arrest of spermatogenesis. Yet, this is purely hypothetical and needs to be further tested. Furthermore, duplications of this region have been observed in proven fertile fathers in a diagnostic setting. Therefore, it is less likely that the duplication of the CATSPER2 gene will be causative for the maturation arrest observed in our patient. Homozygous deletions of the CATSPER2 gene have been reported to be related to male infertility due to the sperm immotility (Carlson et al., 2005; Ho et al., 2009) . The region in which this rearrangement was detected involved two more genes: CKMT1B and STRC. A homozygous deletion involving the three genes has been described in patients with male infertility and deafness (Avidan et al., 2003; Zhang et al., 2007) . In our control group, we did not find any duplication as in patient EMA18, though two heterozygous deletions were observed.
Another interesting region includes FAM82A1, at chromosomeband 2p22.2. For patient EMA18 a deletion was observed, including the start codon and predicting a deletion of at least half of the protein (328 amino acids). The remaining copy of the FAM82A1 gene appeared to be intact in EMA18. The FAM82A1 gene has not been studied before, and therefore an association with spermatogenesis and male (in)fertility remains unknown.
On chromosome 12, we detected a deletion removing the complete SIRT4 gene. The human SIRT4 gene is ubiquitously expressed, and localized in mitochondria (Haigis et al., 2006; Ahuja et al., 2007) . The gene SIRT4 is located at 12q24.31. It has ADP-ribosyltransferase activity and is presumably involved in various metabolic processes (Yu and Auwerx, 2009) . In the present study, a hemizygous deletion of this gene was only detected in one infertile man, and not in normozoospermic controls. However, knock-out mice models showed normal reproduction with normal litter sizes, and therefore the deletion of one copy of this gene might not be related to the fertility problems observed in this patient (Haigis et al., 2006) .
In a final rearrangement, the complete C17ORF51 gene is absent in EMA2. In total, we have detected two controls with a duplication of this region, but none with a deletion. The function of this gene also remains to be investigated, so it is hard to anticipate the consequences of a deletion. The remaining copy of the C17ORF51 gene remains intact in patient EMA2.
Of the eight remaining regions, two regions are rearranged in patient EMA18 (involving FAM82A1 and PLSCR2) and two regions are duplicated in EMA8 (involving among others genes, THRAP3, SH3D21 and CATSPER2). Although in patients with a maturation arrest of spermatogenesis, a single gene defect is anticipated, we should bear in mind that only the contribution of multiple regions might be causative for the fertility problems. This should especially be taken into consideration in patients with severe oligozoospermia.
Overall, three regions containing genes potentially involved in male infertility were detected. Yet, the three genes (CATSPER2, PLSCR2 and SYT6) are involved in the last stages of spermatogenesis or fertilization, and therefore it remains unsure whether duplications or deletions of these genes are involved in a meiotic arrest at the spermatocyte level. One more gene, SLC25A24, has a testis-enriched expression pattern. This gene is a mitochondrial carrier and might be involved in the transport of adenine nucleotides (Fiermonte et al., 2004) . It would be of particular interest to study the consequences of a deletion of SLC25A24 in more detail. Three more genes (C17ORF51, FAM82A1 and SH3D21) are also interesting for further research studies, as their function remains to be elucidated.
Array CGH analysis in male infertility
This is the first study to investigate array CGH in patients with infertility problems showing that potential causative factors can be detected. Yet, more research is necessary for each region to prove a link with male infertility. Furthermore, in this first study, we focused on defects in protein coding genes, thereby excluding a number of rearrangements such as intronic deletions and duplications, non-coding RNAs, pseudogenes etc. Possibly, these rearrangements might be the underlying cause of (part of) the fertility problems as well. In future studies, these regions will be included in our analyses. Moreover, some genes or regions are (currently) not possible to examine since they are present in multiple copies.
As more studies will be performed on larger groups of normozoospermic controls, the knowledge on 'neutral' CNVs will increase. This will make the interpretation of data obtained from patient studies easier. Furthermore, larger studies on unselected groups of patients (which at the same time requires the simultaneous analysis of controls) will be useful to determine whether array CGH should be provided as a routine test in the diagnosis of male infertility. However, currently it is not useful to implement array CGH in a routine day-to-day clinical practice. Nevertheless, this technique is useful in a research setting for identifying genes that are essential for or at least involved in spermatogenesis.
Supplementary data
Supplementary data are available at http://humrep.oxford journals.org/.
